News Column

BRIEF: Alcobra files for $100m Nasdaq offering

July 15, 2014

By Gali Weinreb and Tali Tsipori, Globes, Tel Aviv, Israel

July 15--Alcobra Pharmaceuticals Ltd. (Nasdaq: ADHD), which is developing drugs for treating ADHD has filed a prospectus to raise up to $100 million. The price of the shares in the offering was not indicated. A shelf prospectus is not binding but it indicates that Alcobra has a huge appetite for raising money after already holding two offering in the past 14 months.

Alcobra's IPO on Nasdaq in May 2013 raised $25 million at a company value of $89 million. After the share price rose 200% in just six months, the company held a secondary offering to raise $33 million, lowering its company value by one third to $170 million.

Today Alcobra is worth $260 million and had $44 million in cash at the end of the first quarter. Alcobra came to Nasdaq 14 months ago without cash and almost no expenses and was a company relying on outsourcing. Since then the expenses have accumulated mainly due to clinical trials.

The filing of the prospectus comes as Alcobra announced that patient recruitment for a Phase III clinical trial of its lead product for ADHD treatment has been completed. Results are expected in September, earlier than expected.


(c)2014 the Globes (Tel Aviv, Israel)

Visit the Globes (Tel Aviv, Israel) at

Distributed by MCT Information Services

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Globes (Tel Aviv)

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters